Tics reduces experimental drug in patients with Tourette’s syndrome

“, said study author Donald L. Gilbert, MD, of Cincinnati Children’s Hospital Medical Center in Ohio, and a member of the American Academy of Neurology.

That’s especially true because many sufferers who are taking existing medications still have symptoms of weakness or weight gain or other side effects.. “

The study looked at 149 children and adolescents between the ages of 6 and 17 with Tourette syndrome. They were divided into two groups: 74 treated with ecopipam and 75 treated with a placebo.

The researchers measured the participants’ tic severity using two common tic rating scales at the start of the study and again three months later.

The first test measures motor sensation and voice and has a maximum score of 50.

The second trial looked at overall tic symptoms and severity of tic-related impairment. It has a maximum score of 100. A higher score on either test indicates more severe symptoms and a negative impact on daily life.

After three months, the researchers found that the ecopipam group had less severe and less severe numbness and had better overall results according to both test scores.

On average, participants taking ecopipam improved their motor and speech severity scores from 35 to 24, a 30% reduction. That’s compared with placebo users, who improved from a mean tic severity score of 35 to 28 over the same time period, a 19% reduction.

When the researchers looked at the scores of a second test to assess the overall effectiveness of ecopipam, they found that those taking the drug improved from an average score of 68 to 46, a 32% reduction, compared with those taking the drug. placebo users, who improved from an average score of 66 to 54, decreased by 20%.

Gilbert noted that 34% of participants using ecopipam experienced side effects such as headaches and fatigue, while 21% of those taking a placebo.

Previous research has suggested that problems with dopamine, a neurotransmitter in the brain, may be related to the symptoms of Tourette’s syndrome, and that dopamine D1 receptors play an important role.“Gilbert said.

Dopamine receptors are found in the central nervous system. When they receive dopamine, they generate signals for various mental and physical functions such as movement.

Different receptors help control different functions. While ecopipam is still in the experimental phase, it is the first drug to target the D1 receptor instead of the D2 receptor, which is the drug targeted by existing drugs on the market. Our results demonstrate that ecopipam deserves more research as a possible treatment option for Tourette syndrome in young adults in the future. “

One limitation of the study is its three-month length. Gilbert notes that while this is the norm for this type of study, it’s important to find out if the symptom improvements last longer.

The study was supported by Emalex Biosciences, LLC.

Source: Medindia

Source link


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button